uBriGene Biosciences
Shanghai, CN · Boston, MA
Compare AAV CDMOs in Asia
Compare AAV CDMOs in China
Compare Lentiviral CDMOs in Asia
Compare Lentiviral CDMOs in China
Compare Plasmid DNA CDMOs in Asia
Compare Plasmid DNA CDMOs in China
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
56.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (20)
○ EMA GMP
○ MHRA GMP
Quick Facts: uBriGene Biosciences
- Signal Score
- 56.5/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Shanghai, CN · Boston, MA
- Modalities
- AAV, Lentiviral, Plasmid
- Active Programs
- No ClinicalTrials.gov matches confirmed — 11 partnership signals in press (announcements, not verified)
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About uBriGene Biosciences
Chinese CGT CDMO with US presence. BIOSECURE Act exposure.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 11 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Financial Stability
50.0
BIOSECURE Act exposure risk
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
BIOSECURE Act exposure risk
Capacity
63.0
2 manufacturing sites
Sites: Shanghai, China, Boston, MA
Source: company profiles (manufacturing sites, modality breadth)
2 manufacturing sites
Press Signals20 articles (not scored)
2 manufacturing sites
Hiring Activity 1 open role Beta
From public job postings on uBriGene Biosciences' careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
1
open role
0
in manufacturing, quality, PD/MSAT, engineering or regulatory (0%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 0 taken down.
By function
By site
Germantown, MD
· 1 other 1
· 1 other 1
Latest postings
Associated Director of Marketing
Commercial, BD & client projects · Germantown, MD
Coverage: counted from uBriGene Biosciences' own careers board.
Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source:
ubrigenebiosciences.applytojob.com
· Checked Nov 20, 2026 · Tracking since Oct 26, 2026
Company Signals 20 articles
Company announcements, not verified evidence. They do not change any score.
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Digital Journal
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Digital Journal
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Corsicana Daily Sun
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies corsicanadailysun.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - The Facts
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies The Facts
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Weatherford Democrat
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Weatherford Democrat
uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies - National Today
uBriGene and Cellinfinity BIO Partner to Advance In Vivo CAR-T Therapies National Today
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - PharmiWeb.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies PharmiWeb.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Yahoo Finance
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Yahoo Finance
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - News-Press NOW
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies News-Press NOW
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - The Batesville Daily Guard
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies The Batesville Daily Guard
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Carroll County Mirror-Democrat
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Carroll County Mirror-Democrat
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Scott Coop
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies Scott Coop
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies - Newswire.com
uBriGene and Cellinfinity BIO Announce Strategic Partnership to Advance In Vivo CAR-T Therapies newswire.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Gene - pharmiweb.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Gene PharmiWeb.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - Rutland Herald
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy Rutland Herald
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - BioSpace
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy BioSpace
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - Weatherford Democrat
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy weatherforddemocrat.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - ACCESS Newswire
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy ACCESS Newswire
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - guardonline.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy The Batesville Daily Guard
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - newswire.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy newswire.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - theglobeandmail.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy The Globe and Mail
Frequently Asked Questions About uBriGene Biosciences
What is uBriGene Biosciences's CDMO Signal Score?
uBriGene Biosciences has a Signal Score of 56/100, based on quality, operations, financial stability, and capacity data.
Evaluating uBriGene Biosciences for a manufacturing program?
Use the free AI matchmaker to compare uBriGene Biosciences against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
Ascend Advanced Therapies
Rockville, MD · Alachua, FL · Munich, DE
Signal Score: 78.1
AAV, Lentiviral, Plasmid
Thermo Fisher Scientific
Plainville, MA · Alachua, FL · Cambridge, MA
Signal Score: 77.6
AAV, Lentiviral, Plasmid DNA, Adenoviral, Plasmid, Small Molecule API, Oral Solid Dose, Sterile Fill-Finish
Compare uBriGene Biosciences with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.